Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study by Xiao-Qi Qin, Gang An, Zeng-Jun.

Slides:

Advertisements

Similar presentations

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Advertisements

Who is the best donor for a related HLA haplotype-mismatched transplant? by Yu Wang, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Dai-Hong Liu, Xiao-Hui Zhang,

Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case–Control Study Zhi-Peng.

Volume 79, Issue 1, Pages (January 2013)

Beijing Eye Public Health Care Project

Postconditioning the Human Heart with Adenosine in Heart Valve Replacement Surgery Zhen-Xiao Jin, MD, Jing-Jun Zhou, PhD, Mei Xin, MS, Dao-Rong Peng,

Volume 385, Issue 9984, Pages (June 2015)

Volume 77, Issue 9, Pages (May 2010)

Periodic elevation of regulatory T cells on the day of embryo transfer is associated with better in vitro fertilization outcome Wen-Juan Wang, Fu-Jun.

Volume 16, Pages (February 2017)

Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic.

Circ Cardiovasc Interv

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma Yirui Zhai, MD, Zhouguang Hui, MD, Wei Ji, MD, Xiaozhen Wang,

Outcomes of per-oral endoscopic myotomy for treatment of esophageal achalasia with a median follow-up of 49 months Quan-Lin Li, MD, Qiu-Ning Wu, MD,

Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients Ze Fen Xiao, MD, Zong Yi Yang, MD, Jun Liang, MD, Yan.

Solitary plasmacytoma of bone and asymptomatic multiple myeloma

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Volume 74, Issue 6, Pages (December 2018)

Efficacy and Safety of Abelmoschus manihot for Primary Glomerular Disease: A Prospective, Multicenter Randomized Controlled Clinical Trial Li Zhang,

Association of an Impaired Bone Marrow Microenvironment with Secondary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation Yuan.

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia Lan-Ping Xu, Zheng-Li Xu, Xiao-Hui Zhang, Huan.

Changes in the Hemostatic System of Patients With Acute Aortic Dissection Undergoing Aortic Arch Surgery Xin Liang Guan, MD, Xiao Long Wang, MD, Yu Yong.

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic.

Nonmalignant Late Effects in Survivors of Partially Matched Donor Hematopoietic Stem Cell Transplantation Xiao-Dong Mo, Lan-Ping Xu, Dai-Hong Liu, Xiao-Hui.

High Expression of Zinc-Binding Protein-89 Predicts Decreased Survival in Esophageal Squamous Cell Cancer Shu-Mei Yan, MD, Hui-Ni Wu, MB, Fan He, MD,

Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.

Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan.

Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic.

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based.

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Volume 385, Issue 9984, Pages (June 2015)

Frequency of Polycythemia and Other Abnormalities in a Tibetan Herdsmen Population Residing in the Kham Area of Sichuan Province, China Jian-bo Zhang,

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Sequential Intensified Conditioning and Tapering of Prophylactic Immunosuppressants for Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell.

Positive Results of Serum Galactomannan Assays and Pulmonary Computed Tomography Predict the Higher Response Rate of Empirical Antifungal Therapy in.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

A Genomewide Linkage Scan for Quantitative-Trait Loci for Obesity Phenotypes Hong-Wen Deng, Hongyi Deng, Yong-Jun Liu, Yao-Zhong Liu, Fu-Hua Xu, Hui Shen,

Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group by Tao Wu, Yong Yang, Su-Yu.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia Yu Wang,

Volume 77, Issue 9, Pages (May 2010)

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde,

Identification of a Novel Locus for Marie Unna Hereditary Hypotrichosis to a 17.5 cM Interval at 1p21.1–1q21.3 Sen Yang, Min Gao, Yong Cui, Kai-Lin Yan,

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation:

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Deciphering Pancreatic Islet β Cell and α Cell Maturation Pathways and Characteristic Features at the Single-Cell Level Wei-Lin Qiu, Yu-Wei Zhang, Ye.

Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient by Jian-Ping Zhang, Rui Zhang, Shih-Ting Tsao,

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia,

Evidence for a Novel Psoriasis Susceptibility Locus at 9q33–9q34 in Chinese Hans Liang-Dan Sun, Wei Li, Sen Yang, Xing Fan, Kai-Lin Yan, Yan-Hua Liang,

Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma by Maximilian Merz, Anna Jauch, Thomas Hielscher,

Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma Wei-Wei Chen, MD, Feng Wang, MD, PhD, ShaoBin Chen, MD, Luhua Wang,

Cytotoxic T Lymphocyte Antigen-4 Down-Regulates T Helper 1 Cells by Increasing Expression of Signal Transducer and Activator of Transcription 3 in Acute.

Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease

Presentation transcript:

Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study by Xiao-Qi Qin, Gang An, Zeng-Jun Li, Lan-Ting Liu, Yan Xu, Lin-Hua Yang, Yan-Ping Ma, Shu-Hui Deng, Wei-Wei Sui, Yu Qin, Xiao-Yan Feng, Mei-Rong Zang, Wen-Juan Yang, Yan-Ru Zhang, Shu-Hua Yi, Ting-Yu Wang, Rui Lv, De-Hui Zou, Yao-Zhong Zhao, and Lu-Gui Qiu BloodAdv Volume 3(5):751-760 March 12, 2019 © 2019 by The American Society of Hematology

Xiao-Qi Qin et al. Blood Adv 2019;3:751-760 © 2019 by The American Society of Hematology

Effect of M-protein secretory status on PFS and OS of all patients with MM. Among 4 groups, the median PFS (A) and OS (B) of MM patients was significantly longer in patients with measurable disease than in those with oligosecretory, nonsecretory, and nonproducer MM. Within the unmeasurable group, patients with nonproducer myeloma showed the shortest PFS and OS. Effect of M-protein secretory status on PFS and OS of all patients with MM. Among 4 groups, the median PFS (A) and OS (B) of MM patients was significantly longer in patients with measurable disease than in those with oligosecretory, nonsecretory, and nonproducer MM. Within the unmeasurable group, patients with nonproducer myeloma showed the shortest PFS and OS. Xiao-Qi Qin et al. Blood Adv 2019;3:751-760 © 2019 by The American Society of Hematology

Effect of M-protein secretory status on PFS and OS of patients with MM receiving thalidomide- or bortezomib-based therapy. Effect of M-protein secretory status on PFS and OS of patients with MM receiving thalidomide- or bortezomib-based therapy. The median PFS and OS of MM patients was significantly longer in patients with measurable disease than in those with oligosecretory, nonsecretory, and nonproducer MM regardless of thalidomide- (A-B) or bortezomib-based (C-D) therapy. Within the unmeasurable group, patients with nonproducer myeloma showed the shortest PFS and OS. Xiao-Qi Qin et al. Blood Adv 2019;3:751-760 © 2019 by The American Society of Hematology

Survival of newly diagnosed patients with MM with different M-protein secretory status after receiving thalidomide- or bortezomib-based therapy. Survival of newly diagnosed patients with MM with different M-protein secretory status after receiving thalidomide- or bortezomib-based therapy. PFS and OS were remarkably extended with chemotherapy incorporating the proteasome inhibitor bortezomib in patients with measurable disease (A-B), but not in patients with unmeasurable disease (C-D). Xiao-Qi Qin et al. Blood Adv 2019;3:751-760 © 2019 by The American Society of Hematology